Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS: During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with placebo, OM reduced incidence of the primary outcome over 22 months of follow-up (37.0% vs 39.1%; HR, 0.92 [95% CI 0.85-0.99]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationRegularization Paths for Cox's Proportional Hazards Model via Coordinate Descent
Simon, N., Friedman, J., Hastie, T., & Tibshirani, R. (2011) · Journal of Statistical Software · doi:10.18637/jss.v039.i05 · Cited by 2,499
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationCardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Malik, F. I., Hartman, J. J., Elias, K. A., Morgan, B. P., Rodriguez, H., Brejc, K., Anderson, R. L., Sueoka, S. H., Lee, K. H., Finer, J. T., et al. (2011) · Science · doi:10.1126/science.1200113 · Cited by 584
Self-citationRepeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
Kramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Cited by
Items 201–300 of 709
Bánfi‐Bacsárdi, F., Muk, B., Pilecky, D., Duray, G. Z., Kiss, R. G., & Nyolczas, N. (2022) · Cardiology · doi:10.1159/000528505 · Cited by 17
Modern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
Popa, I. P., Haba, M. Ș. C., Maranducă, M. A., Tănase, D. M., Șerban, D. N., Șerban, L., Iliescu, R., & Tudorancea, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091964 · Cited by 18
New Targets in Heart Failure Drug Therapy
Correale, M., Tricarico, L., Fortunato, M., Mazzeo, P., Nodari, S., Biase, M. D., & Brunetti, N. D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.665797 · Cited by 17
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure: A Meta-Analysis
Sayed, A. A., ElRefaei, M., Awad, K., Salah, H., Mandrola, J. M., & Foy, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.46684 · Cited by 17
Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
Trivedi, A., Oberoi, R. K., Jafarinasabian, P., Zhang, H., Flach, S. D., Abbasi, S. A., Dutta, S., & Lee, E. W. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01014-0 · Cited by 17
Self-citationDocherty, K. F., McMurray, J. J. V., Claggett, B. L., Miao, Z. M., Adams, K. F., Arias‐Mendoza, A., Cleland, J. G. F., Díaz, R., Echeverría, L. E., Felker, G. M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2763 · Cited by 17
Self-citationPreventing hypocontractility-induced fibroblast expansion alleviates dilated cardiomyopathy
Bretherton, R. C., Reichardt, I. M., Zabrecky, K. A., Nagle, A., Bailey, L. R. J., Bugg, D., Smolgovsky, S. A., Gifford, A. L., McMillen, T. S., Goldstein, A. J., et al. (2025) · Science · doi:10.1126/science.adv9157 · Cited by 17
Frameshift variants in C10orf71 cause dilated cardiomyopathy in human, mouse, and organoid models
Li, Y., Ma, K., Dong, Z., Gao, S., Zhang, J., Huang, S., Yang, J., Fang, G., Li, Y., Li, X., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci177172 · Cited by 17
Tang, H., Germinal, K., Milfort, A., Chen, W., Chang, S., Huang, W., Li, Y., Lu, Y., Ahmed, M. M., Kimmel, S. E., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04339-3 · Cited by 16
Parikh, J., Rumbell, T. H., Butova, X., Myachina, T. A., Acero, J. C., Khamzin, S., Solovyova, O. E., Kozloski, J., Khokhlova, A., & Gurev, V. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09787-4 · Cited by 16
Tailored therapeutics for cardiomyopathies
Bakalakos, A., Monda, E., & Elliot, P. M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01183-6 · Cited by 16
Spall, H. G. C. V., Averbuch, T., Damman, K., & Voors, A. A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2248 · Cited by 16
Self-citationDębska-Kozłowska, A., Książczyk, M., & Lelonek, M. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10120-x · Cited by 16
Silva‐Cardoso, J., Fonseca, C., Franco, F., Morais, J., Ferreira, J., & Brito, D. A. (2021) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2021.07.009 · Cited by 16
Self-citationCunningham, J. W., Chatur, S., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., Esperón, G. L., Lam, C. S. P., Sato, N., Senni, M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0016 · Cited by 16
Self-citationRomero, A., Ashcraft, L. W., Chandra, A., DiMassa, V., Cremin, P. A., Collibee, S. E., Chuang, C.-Y., Hartman, J. J., Hwee, D. T., Jean, D. J. S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02413 · Cited by 16
Self-citationWomen and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Assessing Cardiac Contractility From Single Molecules to Whole Hearts
Garg, A., Lavine, K. J., & Greenberg, M. J. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.07.013 · Cited by 15
Consistency of HFrEF treatment effect in underrepresented groups in randomized clinical trials
Baudry, G., Monzo, L., Petrie, M. C., Girerd, N., Piña, I. L., Mebazaa, A., Butler, J., Abid, L., Zannad, F. M., & Spall, H. G. C. V. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00028-4 · Cited by 15
Self-citationAdvances in contemporary medical management to treat patients with heart failure
Velez, M. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001021 · Cited by 15
Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure
Rao, B., Speight, C. D., Allen, L. A., Halpern, S. D., Ko, Y., Matlock, D. D., Moore, M. A., Morris, A. A., Scherer, L. D., Thomson, M. C., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023789 · Cited by 15
Muk, B., Pilecky, D., Bánfi‐Bacsárdi, F., Füzesi, T. P., Gergely, T. G., Komáromi, A., Papp, E., Szőnyi, M. D., Forrai, Z., Kazay, Á., et al. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33045 · Cited by 15
Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery
Khomtchouk, B. B., Lee, Y. S., Khan, M. L., Sun, P., Mero, D., & Davidson, M. H. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2047645 · Cited by 15
Nakanishi, T., Oyama, K., Tanaka, H., Kobirumaki-Shimozawa, F., Ishii, S., Terui, T., Ishiwata, S., & Fukuda, N. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.947206 · Cited by 15
Transition to Advanced Heart Failure: From Identification to Improving Prognosis
Tepetes, N.-I., Kourek, C., Papamichail, A., Xanthopoulos, A. V., Kostakou, P. M., PARASKEVAIDIS, I. A., & Briasoulis, Α. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12030104 · Cited by 15
Correale, M., Mazzeo, P., Tricarico, L., Croella, F., Fortunato, M., Magnesa, M., Amatruda, M., Alfieri, S., Ferrara, S., Ceci, V., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01166-2 · Cited by 14
Advances in Clinical Cardiology 2020: A Summary of Key Clinical Trials
Kearney, A., Linden, K., Savage, P., & Menown, I. B. A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01711-z · Cited by 14
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
Self-citationMapelli, M., Rubbo, F. M., Costantino, S., Amelotti, N., & Agostoni, P. (2025) · Cardiac failure review · doi:10.15420/cfr.2024.37 · Cited by 14
Armijo, J. P., Aguilera, J. L., Manzanares, R. G., Pericet-Rodríguez, C., Castillo, J. C., Campos, G. M. H., Roldán-Guerra, Á., Urbano-Sánchez, C., Mesa, L. B., Caño, N. A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186082 · Cited by 14
Medical management of acute heart failure
Kamran, H., & Tang, W. H. W. (2021) · Faculty Reviews · doi:10.12703/r/10-82 · Cited by 14
Kourek, C., Briasoulis, Α., Papamichail, A., Xanthopoulos, A. V., Tsougos, E., Farmakis, D. T., & PARASKEVAIDIS, I. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063113 · Cited by 14
Effect of the Novel Myotrope Danicamtiv on Cross‐Bridge Behavior in Human Myocardium
Choi, J. H., Holmes, J. B., Campbell, K. S., & Stelzer, J. E. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030682 · Cited by 14
Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift?
Javed, S., & Halliday, B. P. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.24 · Cited by 14
Enzan, N., Miyazawa, K., Koyama, S., Kurosawa, R., Ieki, H., Yoshida, H., Takechi, F., Fukuyama, M., Osako, R., Tomizuka, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64659-6 · Cited by 13
Januzzi, J. L., Tan, X., Yang, L., Brady, J. E., Yang, M., Banka, P., & Lautsch, D. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13749 · Cited by 13
Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis
Alqatati, F., Elbahnasawy, M., Bugazia, S., Ragab, K. M., Elsnhory, A. B., Shehata, M., Elsayed, S. M., Fathy, M. A., & Nourelden, A. Z. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.03.005 · Cited by 13
Lactylation regulates cardiac function
Ghosh-Choudhary, S. K., & Finkel, T. (2023) · Cell Research · doi:10.1038/s41422-023-00857-5 · Cited by 13
Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond
Morelli, M. C., Ingrasciotta, G., Jacoby, D. L., Masri, A., & Olivotto, I. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.04.020 · Cited by 13
Clinical Features and Outcomes of Pediatric MYH7 ‐Related Dilated Cardiomyopathy
de Frutos, F., Ochoa, J. P., Webster, G., Jansen, M., Pérez, P. R., Rasmussen, T. B., Molina, M. S., Villa, R. B., Girolami, F., César, S., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036208 · Cited by 13
Jani, V., Qian, W., Yuan, S., Irving, T. C., & Ma, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314517 · Cited by 13
Bánfi‐Bacsárdi, F., Vámos, M., Majoros, Z., Török, G., Pilecky, D., Duray, G. Z., Kiss, R. G., Nyolczas, N., & Muk, B. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32836 · Cited by 12
Cowie, M., Bozkurt, B., Butler, J., Briggs, A. H., Kubin, M., Jonas, A., Adler, A., Patrick‐Lake, B., & Zannad, F. M. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.020 · Cited by 12
Self-citationAlhakak, A. S., Olsen, F. J., Skaarup, K. G., Lassen, M. C. H., Johansen, N. D., Jørgensen, P. G., Abildgaard, U., Jensen, G. B., Schnohr, P., Søgaard, P., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02269-2 · Cited by 12
Self-citationNew Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events
Lavalle, C., Lullo, L. D., Jabbour, J. P., Palombi, M., Trivigno, S., Mariani, M. V., Summaria, F., Severino, P., Badagliacca, R., Miraldi, F., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226956 · Cited by 12
Halder, S. S., Rynkiewicz, M. J., Kim, L., Barry, M. E., Zied, A. G. A., Sewanan, L. R., Kirk, J. A., Moore, J. R., Lehman, W., & Campbell, S. G. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179135 · Cited by 12
Allen, L. A., Teerlink, J. R., Gottlieb, S. S., Ahmad, T., Lam, C. S. P., & Psotka, M. A. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008594 · Cited by 12
Self-citationProposed New Conceptualization for Definition of Decompensated HF
Bozkurt, B. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.02.001 · Cited by 12
Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice
Sinagra, G., Pagura, L., Stolfo, D., Fabris, E., Savarese, G., Rapezzi, C., Ferrari, R., & Merlo, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.017 · Cited by 12
Guidetti, F., Arrigo, M., Frank, M., Mikulicic, F., Sokolski, M., Aser, R., Wilhelm, M. J., Flammer, A. J., Ruschitzka, F. T., & Winnik, S. H. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.05.013 · Cited by 12
Myofilament Alterations Associated with Human R14del-Phospholamban Cardiomyopathy
Kumar, M., Haghighi, K., Koch, S. E., Rubinstein, J., Stillitano, F., Hajjar, R. J., Kranias, E. G., & Sadayappan, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032675 · Cited by 12
Ráduly, A. P., Tóth, A., Sárkány, F., Horváth, B., Szentandrássy, N., Nánási, P. P., Csanádi, Z., Edes, I. F., Papp, Z., & Borbély, A. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14300 · Cited by 12
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy
Lakdawala, N. K., Hershberger, R. E., García‐Pavía, P., Elliot, P. M., Ginns, J. N., Meder, B., Solomon, S. D., Cunningham, J. W., Gimeno, J. R., Villa, R. B., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1511 · Cited by 12
Self-citationNovel Therapies to Reduce Rehospitalization Risk in Worsening Heart Failure
Lima, I. G. C. V., Nunes, J. T., Godoy, L. C., McDonald, M., & Bocchi, E. A. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101451 · Cited by 11
Zhu, L., Wang, W., Ren, C., Wang, Y., Zhang, G., Liu, J., & Wang, W. (2022) · Biomedicines · doi:10.3390/biomedicines10020402 · Cited by 11
Latest pharmaceutical approaches across the spectrum of heart failure
Bismpos, D., Wintrich, J., Hoevelmann, J., & Böhm, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10389-8 · Cited by 11
Self-citationWong, J. A., Roberts, J. D., & Healey, J. S. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.01.024 · Cited by 11
Ostrominski, J. W., & Vaduganathan, M. (2022) · Clinical Cardiology · doi:10.1002/clc.23849 · Cited by 11
Pediatric heart failure: Current approach and treatment
Olsen, B. A., & Miyamoto, S. D. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100331 · Cited by 11
Chen, A., Zhang, Y., & Zhang, J. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15062 · Cited by 11
Heart failure evidence update 2026
Liori, S., Kapelios, C. J., Savarese, G., & Filippatos, G. S. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10609-3 · Cited by 10
Self-citationYoshikawa, T. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.02.008 · Cited by 10
New Drugs for Heart Failure: What is the Evidence in Older Patients?
Orso, F., Herbst, A., Pratesi, A., Fattirolli, F., Ungar, A., Marchionni, N., & Baldasseroni, S. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.011 · Cited by 10
Ferro, A., Segreti, A., Crispino, S. P., Cricco, R., Cristo, A. D., Ciancio, M., Gurrieri, F., Ussia, G. P., & Grigioni, F. (2025) · Genes · doi:10.3390/genes16070801 · Cited by 10
Lee, M. M. Y., & Masri, A. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00620-2 · Cited by 10
Repetitive milrinone therapy in ambulatory advanced heart failure patients
Laufer‐Perl, M., Sadon, S., Zahler, D., Milwidsky, A., Sadeh, B., Sapir, O. P. R., Granot, Y. N., Korotetski, L., Ketchker, L., Rosh, M., et al. (2022) · Clinical Cardiology · doi:10.1002/clc.23802 · Cited by 10
Reis, J., Gonçalves, A. V., Moreira, R. I., da Silva, T. P., Timóteo, A. T., Pombo, D., Carvalho, T., Correia, C., Santos, C., & Ferreira, R. C. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.03.006 · Cited by 10
Shoji, S., & Mentz, R. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10412-y · Cited by 10
Díez‐Villanueva, P., Jiménez-Méndez, C., Pérez-Rivera, J.-Á., Esteban‐Fernández, A., Datino, T., Martínez‐Sellés, M., & Ayesta, A. (2023) · Cardiology · doi:10.1159/000530424 · Cited by 10
Trivedi, A., Sohn, W. Y., Kulkarni, P., Jafarinasabian, P., Zhang, H., Spring, M., Flach, S. D., Abbasi, S. A., Wahlstrom, J. L., Lee, E. W., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.13118 · Cited by 10
Self-citationTrivedi, A., Wahlstrom, J. L., Mackowski, M., Dutta, S., & Lee, E. B. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000444 · Cited by 10
Mahmud, Z., Tikunova, S. B., Belevych, N., Wagg, C. S., Zhabyeyev, P., Liu, P. B., Rasicci, D. V., Yengo, C. M., Oudit, G. Y., Lopaschuk, G. D., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.892979 · Cited by 10
Genetic Testing as a Guide for Treatment in Dilated Cardiomyopathies
García-Hernández, S., & Iglesias, L. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01772-8 · Cited by 10
Hałas, M., Langa, P., Warren, C. M., Goldspink, P. H., Wolska, B. M., & Solaro, R. J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.121.000420 · Cited by 10
Eder, M. D., Griffin, M. D., Moreno-Villagómez, J., Bellumkonda, L., Maulion, C., Asher, J. L., Wilson, F. P., Cox, Z. L., Ivey-Miranda, J. B., Rao, V. S., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.04.002 · Cited by 10
Identifying Treatments for Stage C2 Heart Failure
Yancy, C. W., Hernandez, A. F., & Fonarow, G. C. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.4024 · Cited by 10
Myosin modulators move forward with FDA approval of mavacamten
Chin, A. C., & Day, S. M. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00093-x · Cited by 9
Morillas, H., Galcerá, E., Alania-Torres, E., Seller, J., Larumbe, A., Núñez, J. E., & Valle, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2304139 · Cited by 9
Representation of Black patients in heart failure clinical trials
Azam, T. U., & Colvin, M. M. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000849 · Cited by 9
Harrington, J., Sun, J., Fonarow, G. C., Heitner, S. B., Divanji, P., Binder, G., Allen, L. A., Alhanti, B., Yancy, C. W., Albert, N. M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028820 · Cited by 9
Self-citationBreaking new ground in heart failure management: novel therapies and future frontiers
Khalid, A., Rodriguez, P., Tasouli-Drakou, V., Ahmed, A.-B., Thatcher, S., Dugal, J. K., & Singh, A. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1643971 · Cited by 9
Mareev, Y. V., Gilarevsky, S. R., Begrambekova, Y. L., Lopatin, Y. M., Анатольевна, Г. А., Duplyakov, D. V., Kobalava, Z. D., Golukhova, E. Z., Koziolova, N. A., Панов, А. В., et al. (2021) · Kardiologiia · doi:10.18087/cardio.2021.4.n1639 · Cited by 9
Romanò, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145090 · Cited by 9
Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update
Hellenkamp, K., Nolte, K., & von Haehling, S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2047647 · Cited by 9
Núñez‐Marín, G., Iraola-Viana, D., Lorenzo, M., de la Espriella, R., Villar, S., Santas, E., Miñana, G., Sanchís, J. M., Carratalá, A., Miró, Ò., et al. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2216386 · Cited by 9
Drug Treatment of Heart Failure in Children: Gaps and Opportunities
Weisert, M., Su, J. A., Menteer, J., Shaddy, R. E., & Kantor, P. F. (2022) · Pediatric Drugs · doi:10.1007/s40272-021-00485-9 · Cited by 9
What Is the Status of Regenerative Therapy in Heart Failure?
Kir, D., Patel, M. J., & Munagala, M. R. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01575-3 · Cited by 9
Mechanoenergetische Defekte bei Herzinsuffizienz
Maack, C. (2023) · Herz · doi:10.1007/s00059-022-05161-3 · Cited by 9
Morbach, C., Simon, I., Danner, E., Gelbrich, G., Stefenelli, U., Sahiti, F., Scholz, N., Cejka, V., Albert, J., Ertl, G., et al. (2023) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyad020 · Cited by 9
Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis
Ono, R., Chimura, M., Docherty, K. F., Henderson, A. D., Campbell, R. T., Desai, A. S., Komajda, M., Packer, M., Pfeffer, M. A., Pitt, B., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag341 · Cited by 9
Self-citationCardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats
Collibee, S. E., Romero, A., Muci, A. R., Hwee, D. T., Chuang, C.-Y., Hartman, J. J., Motani, A. S., Ashcraft, L. W., deRosier, A., Grillo, M. P., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02412 · Cited by 9
Self-citationOmecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword
Amesz, J. H., Langmuur, S. J. J., Bierhuizen, M. F. A., de Groot, N. M. S., Manintveld, O. C., & Taverne, Y. J. H. J. (2023) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2023.100040 · Cited by 9
Fucili, A., Cimaglia, P., Severi, P., Giannini, F., Boccadoro, A., Micillo, M., Rapezzi, C., Tavazzi, L., & Ferrari, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194325 · Cited by 8
Advances in the management of acute decompensated heart failure
Gottlieb, M. A., Bellolio, F., Long, B., & Storrow, A. B. (2025) · BMJ · doi:10.1136/bmj-2025-084242 · Cited by 8
Villevalde, S. V., & Soloveva, A. E. (2021) · Kardiologiia · doi:10.18087/cardio.2021.12.n1860 · Cited by 8
Greene, S. J., Lautsch, D., Gaggin, H. K., Djatche, L. M., Zhou, M., Song, Y., Signorovitch, J., Stevenson, A. S., Blaustein, R. O., & Butler, J. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.016 · Cited by 8
Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
Milinković, I., Polovina, M. M., Coats, A. J. S., Rosano, G. M. C., & Seferovic, P. M. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.14 · Cited by 8
Vrachatis, D. A., Papathanasiou, K. A., Giotaki, S. G., Raisakis, K., Kaoukis, A., Kossyvakis, C., Theodorakis, A., Pediotidis, S., Avramides, D., Siasos, G., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230316142450 · Cited by 8
Peters, A. E., Mentz, R. J., Sun, J., Harrington, J., Fudim, M., Alhanti, B., Hernandez, A. F., Butler, J., Starling, R. C., & Greene, S. J. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.05.010 · Cited by 8
Solaro, R. J., Goldspink, P. H., & Wolska, B. M. (2024) · Biomedicines · doi:10.3390/biomedicines12050999 · Cited by 8
Metadata
- Authors
- Teerlink, J. R., Diaz, R., Felker, G. M., McMurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sørensen, T., Böhm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlström, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Macdonald, P., Mareev, V., Momomura, S.-I., O’Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., & Kurtz, C. E.
- Affiliations
- San Francisco VA Medical Center (US)
- From the Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California, San Francisco, San Francisco (J.R.T.), Amgen, Thousand Oaks (L.S., J.C.L., N.H., S.A.A., C.E.K.), and Cytokinetics, South San Francisco (F.I.M.) — all in California; Estudios Clínicos Latino América, Rosario, Argentina (R.D.); the Division of Cardiology, Duke University School of Medicine and Duke Clinical Research Institute, Durham (G.M.F.), and the University of North...
- Brigham and Women's Hospital (US)
- University of North Carolina at Chapel Hill (US)
- University of Minnesota (US)
- Linköping University (SE)
- University of Bern (CH)
- ORCID
- Teerlink, John R.
- Felker, G. Michael
- McMurray, John J.V.
- Metra, Marco
- Solomon, Scott D.
- Anand, Inder
- Böhm, Michael
- Bonderman, Diana
- Cleland, John G.F.
- Dahlström, Ulf
- Fang, James C.
- Filippatos, Gerasimos
- Fonseca, Cândida
- Goudev, Assen R.
- Howlett, Jonathan G.
- Lanfear, David E.
- Li, Jing
- Lund, Mayanna
- Macdonald, Peter
- Momomura, Shin-ichi
- O’Meara, Eileen
- Parkhomenko, Alexander
- Ponikowski, Piotr
- Sliwa, Karen
- Voors, Adriaan A.
- Zannad, Faiez
- Abbasi, Siddique A.
- Malik, Fady I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-14
- Volume
- 384
- Issue
- 2
- Pages
- 105-116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3098430919
- Cited by
- 656
- References
- 26
- Citations by year
- 2026: 51 · 2025: 84 · 2024: 76 · 2023: 150 · 2022: 130 · 2021: 148
- FWCI
- 68.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- RUC (Universidade Da Coruña) (submittedVersion)
- Funders
- Amgen
- Cytokinetics Inc.
- Servier
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- omecamtiv mecarbil, cardiac myosin activator, heart failure with reduced ejection fraction, cardiovascular outcomes, heart failure hospitalization, cardiovascular mortality, N-terminal pro-brain natriuretic peptide, cardiac troponin I, symptom burden, pharmacokinetic-guided dosing, ventricular arrhythmias
- MeSH terms
- Aged, Aged, 80 and over, Cardiotonic Agents, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Myocardial Contraction, Stroke Volume, Urea, Cardiac Myosins, Heart Failure, Systolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.